litlas
Log inCreate account

Robert A. Copeland

Active 1988–2025

80
Papers
24,623
Citations
69
h-index
78
i10-index

Citations

Citations per year for Robert A. Copeland1973: 1 citations1984: 1 citations1991: 1 citations1992: 6 citations1993: 6 citations1994: 1 citations1995: 10 citations1996: 22 citations1997: 22 citations1998: 27 citations1999: 60 citations2000: 174 citations2001: 193 citations2002: 211 citations2003: 190 citations2004: 162 citations2005: 143 citations2006: 137 citations2007: 131 citations2008: 118 citations2009: 169 citations2010: 156 citations2011: 222 citations2012: 227 citations2013: 281 citations2014: 332 citations2015: 359 citations2016: 400 citations2017: 463 citations2018: 340 citations2019: 958 citations2020: 846 citations2021: 829 citations2022: 669 citations2023: 460 citations2024: 645 citations2025: 268 citations2026: 23 citations1974–1983: no citations, so these years are not shown1985–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,262 citing papers, 32.1% of this breakdownChina: 1,001 citing papers, 9.9% of this breakdownUnited Kingdom: 858 citing papers, 8.5% of this breakdownGermany: 610 citing papers, 6% of this breakdownCanada: 422 citing papers, 4.2% of this breakdownItaly: 377 citing papers, 3.7% of this breakdownJapan: 345 citing papers, 3.4% of this breakdownFrance: 321 citing papers, 3.2% of this breakdownSwitzerland: 216 citing papers, 2.1% of this breakdownAustralia: 197 citing papers, 1.9% of this breakdownIndia: 191 citing papers, 1.9% of this breakdownSpain: 187 citing papers, 1.8% of this breakdown
0%32.1%Other 21.3%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology55.2%
  • Medicine27.7%
  • Computer Science5.1%
  • Chemistry3.2%
  • Immunology and Microbiology2.5%
  • Neuroscience2.5%
  • Other3.8%

Topics

  • Epigenetics and DNA Methylation6.6%
  • Cancer-related gene regulation4.4%
  • Computational Drug Discovery Methods3.8%
  • Protein Degradation and Inhibitors3.1%
  • RNA modifications and cancer2.6%
  • Histone Deacetylase Inhibitors Research2.4%
  • Other77.1%

Coauthors

All papers

Open in search
  1. Drug–target residence time and its implications for lead optimization

    Authors: Robert A. Copeland, David L. Pompliano, Thomas D. Meek - Nature Reviews Drug Discovery 2006 cited by 1,446

  2. The drug–target residence time model: a 10-year retrospective

    Authors: Robert A. Copeland - Nature Reviews Drug Discovery 2015 cited by 733

  3. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

    Authors: Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, Jean‐Marie Michot, Carlo Lucchesi, Andréa Varga, Jean‐Michel Coindre, Stephen J. Blakemore, Alicia Clawson, Benjamin Suttle, Alice McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A. Copeland, Peter Ho, Vincent Ribrag - The Lancet Oncology 2018 cited by 614

  4. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

    Authors: Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock, Kevin W. Kuntz, Heike Keilhack - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 782

  5. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

    Authors: Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien, Sarah V. Gerhart, Lorna H. Mitchell, Nicholas D. Adams, Nathalie Rioux, Trupti Lingaraj, Scott Ribich, Melissa B. Pappalardi, Niyant Shah, Jenny Laraio, Yan Liu, Michael Butticello, Chris Carpenter, Caretha L. Creasy, Susan Korenchuk, Michael T. McCabe, Charles F. McHugh, Raman P. Nagarajan, Craig D. Wagner, Francesca Zappacosta, Roland S. Annan, N.O. Concha, Roberta Thomas, Timothy K. Hart, J. Joshua Smith, Robert A. Copeland, Mikel P. Moyer, John Campbell, Kim Stickland, James E. Mills, Suzanne Jacques-O’Hagan, Christina J. Allain, Danielle Johnston, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Kerren K. Swinger, Ann Boriack-Sjodin, Tom Riera, Gideon Shapiro, Richard Chesworth, Rabinder Prinjha, Ryan G. Kruger, Olena Barbash, Helai P. Mohammad - Cancer Cell 2019 cited by 347

  6. The promise and peril of chemical probes

    Authors: C.H. Arrowsmith, James E. Audia, Christopher P. Austin, Jonathan B. Baell, Jonathan P. Bennett, Julian Blagg, C. Bountra, Paul E. Brennan, Peter J. Brown, Mark E. Bunnage, Carolyn Buser‐Doepner, Robert M Campbell, Adrian J. Carter, Philip Cohen, Robert A. Copeland, Ben Cravatt, Jayme L. Dahlin, Dashyant Dhanak, A.M. Edwards, Mathias Frederiksen, Stephen V. Frye, Nathanael S. Gray, Charles E. Grimshaw, David Hepworth, Trevor Howe, K. Huber, Jian Jin, Stefan Knapp, Joanne Kotz, Ryan G. Kruger, Derek Lowe, Mary M. Mader, Brian D. Marsden, Anke Mueller‐Fahrnow, Susanne Müller, Rónán C. O’Hagan, John P. Overington, Dafydd R. Owen, Saul H. Rosenberg, Ruth A. Ross, Bryan L. Roth, Matthieu Schapira, Stuart L. Schreiber, Brian K. Shoichet, M. Sundström, Giulio Superti-Furga, Jack Taunton, Leticia Toledo‐Sherman, Chris Walpole, Michael A. Walters, Timothy M. Willson, Paul Workman, Robert N. Young, William J. Zuercher - Nature Chemical Biology 2015 cited by 850

  7. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

    Authors: Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Aravind Basavapathruni, Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock - Blood 2013 cited by 725

  8. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

    Authors: Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer, P. Ann Boriack‐Sjodin, Tim J. Wigle, L. Danielle Johnston, Nathalie Rioux, Michael J. Munchhof, Lei Jin, Suzanne L. Jacques, Kip A. West, Trupti Lingaraj, Kimberly Stickland, Scott Ribich, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Roy M. Pollock, J. Joshua Smith, Olena Barbash, Melissa B. Pappalardi, Thau Ho, Kelvin Nurse, Khyati Oza, Kathleen T. Gallagher, Ryan G. Kruger, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth, Kenneth W. Duncan - Nature Chemical Biology 2015 cited by 546

  9. Evaluation of Enzyme Inhibitors in Drug Discovery

    Authors: Robert A. Copeland - 2013 cited by 673

  10. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

    Authors: Robert A. Copeland - 2005 cited by 1,061

  11. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

    Authors: Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Christina R. Majer, Christopher J. Sneeringer, Jeffrey Song, L. Danielle Johnston, Margaret Porter Scott, J. Joshua Smith, Yonghong Xiao, Lei Jin, Kevin W. Kuntz, Richard Chesworth, Mikel P. Moyer, Kathrin M. Bernt, Jen‐Chieh Tseng, Andrew L. Kung, Scott A. Armstrong, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock - Cancer Cell 2011 cited by 934

  12. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

    Authors: Christopher J. Sneeringer, Margaret Porter Scott, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 680

  13. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

    Authors: Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan‐Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Nigel J. Waters, J. Joshua Smith, Margaret Porter-Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Toshimitsu Uenaka, Roy M. Pollock, Kevin W. Kuntz, Akira Yokoi, Heike Keilhack - Molecular Cancer Therapeutics 2014 cited by 522

  14. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

    Authors: Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, Christopher J. Sneeringer, Christina J. Allain, Christine R. Klaus, Joelle D. Sacks, Alejandra Raimondi, Christina R. Majer, Jeffrey Song, Margaret Porter Scott, Lei Jin, J. Joshua Smith, Edward J. Olhava, Richard Chesworth, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Heike Keilhack, Roy M. Pollock, Kevin W. Kuntz - Nature Chemical Biology 2012 cited by 761

  15. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

    Authors: Kenneth W. Wood, Latesh Lad, Lusong Luo, Xiangping Qian, Steven D. Knight, Neysa Nevins, Katjuša Brejc, David Sutton, Aidan G. Gilmartin, Penelope Chua, Radhika Desai, Stephen P. Schauer, Dean E. McNulty, Roland S. Annan, Lisa D. Belmont, Carlos Vázquez García, Yan Lee, Melody Diamond, Leo F. Faucette, Michele Giardiniere, ShuYun Zhang, Chiu-Mei Sun, Justin D. Vidal, Serge Lichtsteiner, William D. Cornwell, Joel Greshock, Richard Wooster, Jeffrey T. Finer, Robert A. Copeland, Pearl S. Huang, David J. Morgans, Dashyant Dhanak, Gustave Bergnes, Roman Sakowicz, Jeffrey R. Jackson - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 254

  16. RNA-modifying proteins as anticancer drug targets

    Authors: P. Ann Boriack‐Sjodin, Scott Ribich, Robert A. Copeland - Nature Reviews Drug Discovery 2018 cited by 156

  17. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

    Authors: Allison E. Drew, Oscar Moradei, Suzanne L. Jacques, Nathalie Rioux, Ann Boriack-Sjodin, Christina J. Allain, Margaret Porter Scott, Lei Jin, Alejandra Raimondi, Jessica L. Handler, Heidi M. Ott, Ryan G. Kruger, Michael T. McCabe, Christopher J. Sneeringer, Thomas V. Riera, Gideon Shapiro, Nigel J. Waters, Lorna H. Mitchell, Kenneth W. Duncan, Mikel P. Moyer, Robert A. Copeland, J. Joshua Smith, Richard Chesworth, Scott Ribich - Scientific Reports 2017 cited by 136

  18. Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function

    Authors: Peter J. Tummino, Robert A. Copeland - Biochemistry 2008 cited by 546

  19. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

    Authors: Kenneth W. Duncan, Nathalie Rioux, P. Ann Boriack‐Sjodin, Michael J. Munchhof, Lawrence A. Reiter, Christina R. Majer, Lei Jin, L. Danielle Johnston, Elayne Chan-Penebre, Kristy G. Kuplast, Margaret Porter Scott, Roy M. Pollock, Nigel J. Waters, J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth - ACS Medicinal Chemistry Letters 2015 cited by 151

  20. Protein methyltransferases as a target class for drug discovery

    Authors: Robert A. Copeland, Michael E. Solomon, Victoria M. Richon - Nature Reviews Drug Discovery 2009 cited by 458

  21. The importance of binding kinetics and drug–target residence time in pharmacology

    Authors: Kevin E. Knockenhauer, Robert A. Copeland - British Journal of Pharmacology 2023 cited by 69

  22. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase

    Authors: Margaret Favata, Kurumi Y. Horiuchi, Elizabeth J. Manos, Andrea J. Daulerio, Deborah A. Stradley, Wendi S. Feeser, Drew E. Van Dyk, William J. Pitts, Richard A. Earl, Frank W. Hobbs, Robert A. Copeland, Ronald L. Magolda, Peggy Scherle, James M. Trzăskos - Journal of Biological Chemistry 1998 cited by 3,029

  23. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

    Authors: Kevin W. Kuntz, John E. Campbell, Heike Keilhack, Roy M. Pollock, Sarah K. Knutson, Margaret Porter-Scott, Victoria M. Richon, Chris Sneeringer, Tim J. Wigle, Christina J. Allain, Christina R. Majer, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth - Journal of Medicinal Chemistry 2016 cited by 171

  24. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor

    Authors: Glenn S. Van Aller, Jeff D. Carson, Wei Tang, Hao Peng, Lin Zhao, Robert A. Copeland, Peter J. Tummino, Lusong Luo - Biochemical and Biophysical Research Communications 2011 cited by 175